Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose Escalation, Safety and Pharmacokinetic, First in Man Study, of SAR566658 Administered as a Single Agent by Intravenous Infusion in Adult Patients With CA6-Positive and Refractory Solid Tumors

NCT01156870 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01156870
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01156870 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose Escalation, Safety and Pharmacokinetic, First in Man Study, of SAR566658 Administered as a Single Agent by Intravenous Infusion in Adult Patients With CA6-Positive and Refractory Solid Tumors
Lead sponsor
Sanofi
Phase
Phase 1
Overall status
Completed
Start date
September 8, 2010
Completion date
April 7, 2017
Enrollment
114 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasm malignant